摘要
目的:探索新辅助化疗^(+)双靶(帕妥珠单抗联合曲妥珠单抗)联合拉帕替尼治疗HER2阳性局部晚期乳腺癌的临床疗效。方法:选取96例单病灶HER2阳性局部乳腺癌患者,根据是否联合拉帕替尼治疗,将其分为联合组与对照组。联合组50例给予新辅助化疗^(+)双靶联合拉帕替尼的综合治疗,对照组46例给予新辅助化疗^(+)双靶治疗,比较两组患者的治疗效果。结果:治疗后,两组患者癌胚抗原(CEA)、糖类抗原15-3(CA15-3)、糖类抗原125(CA125)均较治疗前下降(均P<0.05),其中联合组各指标下降水平优于对照组(均P<0.05)。治疗后,两组患者IgA、IgG、IgM、CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)、NK细胞水平均高于治疗前,CD8^(+)低于治疗前,其中联合组各指标优于对照组(均P<0.05)。治疗后,联合组总有效率为88.00%,对照组为69.56%,联合组优于对照组(P<0.05)。两组不良反应发生率比较差异无统计学意义(P>0.05)。随访1年,联合组生活质量各项评分均高于对照组(均P<0.05)。结论:拉帕替尼辅助治疗局部晚期乳腺癌疗效显著。
Objective:To explore the clinical efficacy of neoadjuvant chemotherapy plus dual target(pertuzumab plus trastuzumab)combined with lapatinib in the treatment of patients with HER2-positive locally advanced breast cancer.Methods:A total of 96 patients with single-lesion HER2-positive locally breast cancer were selected and divided into the combination group and the control group according to whether they were treated with lapatinib or not.Fifty patients in the combined group were treated with neoadjuvant chemotherapy plus dual target drugs combined with lapatinib,and forty-six patients in the control group were treated with neoadjuvant chemotherapy plus dual target drugs therapy.The clinical efficacy of the two groups were compared.Results:After treatment,the levels of carcinoembryonic antigen(CEA),carbohydrate antigen 15-3(CA15-3)and carbohydrate antigen 125(CA125)in the two groups were lower than those before treatment,and the decline levels of each index in the combined group were better than those in the control group(all P<0.05).After treatment,the levels of IgA,IgG,IgM,CD3^(+),CD4^(+),CD4^(+)/CD8^(+)and NK cells in the two groups were higher than those before treatment,and CD8^(+)was lower than that before treatment,and the indexes in the combined group were better than those in the control group(all P<0.05).After treatment,the total effective rate was 88.00%in the combined group and 69.56%in the control group,and the combined group was better than the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).After 1 year of follow-up,the scores of quality of life in the combined group were higher than those in the control group(all P<0.05).Conclusion:Lapatinib is effective for locally advanced breast cancer.
作者
张慧峰
李茉
许淑娣
白跳
ZHANG Huifeng;LI Mo;XU Shudi;BAI Tiao(Ninth Hospital of Xi’an,Xi’an 710054,China)
出处
《陕西医学杂志》
CAS
2023年第5期596-599,共4页
Shaanxi Medical Journal
基金
陕西省卫生健康科研基金资助项目(2018D060)。
